Allergan PLC. (NYSE:AGN) PT Lowered to $200.00

Allergan PLC. (NYSE:AGN) had its price objective reduced by Morgan Stanley from $228.00 to $200.00 in a report released on Thursday, November 2nd. They currently have an equal weight rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Royal Bank Of Canada reaffirmed a buy rating and issued a $285.00 price objective on shares of Allergan PLC. in a research note on Wednesday, September 6th. Credit Suisse Group set a $243.00 price target on shares of Allergan PLC. and gave the company an outperform rating in a report on Tuesday, October 17th. Citigroup Inc. decreased their price objective on shares of Allergan PLC. from $280.00 to $240.00 and set a buy rating for the company in a report on Thursday, October 19th. Cantor Fitzgerald set a $231.00 price objective on shares of Allergan PLC. and gave the stock a hold rating in a report on Wednesday, November 1st. Finally, BidaskClub lowered shares of Allergan PLC. from a buy rating to a hold rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $246.73.

Allergan PLC. (NYSE:AGN) traded down $0.10 during midday trading on Thursday, hitting $171.72. 250,351 shares of the stock traded hands, compared to its average volume of 2,913,987. Allergan PLC. has a one year low of $169.61 and a one year high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $58,005.82, a price-to-earnings ratio of 11.31, a P/E/G ratio of 1.11 and a beta of 1.13.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the previous year, the company earned $3.32 earnings per share. Allergan PLC.’s revenue for the quarter was up 11.4% on a year-over-year basis. equities research analysts expect that Allergan PLC. will post 16.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/morgan-stanley-lowers-allergan-plc-agn-price-target-to-200-00/1750940.html.

Allergan PLC. announced that its board has initiated a share buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently -12.44%.

A number of hedge funds have recently bought and sold shares of AGN. Honeywell International Inc. boosted its position in shares of Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after buying an additional 20,100 shares during the period. Israel Discount Bank of New York acquired a new stake in Allergan PLC. during the first quarter valued at approximately $988,000. Sumitomo Life Insurance Co. raised its stake in Allergan PLC. by 39.0% during the third quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock valued at $3,099,000 after buying an additional 4,244 shares in the last quarter. Colony Group LLC raised its stake in Allergan PLC. by 9.9% during the second quarter. Colony Group LLC now owns 39,802 shares of the company’s stock valued at $9,675,000 after buying an additional 3,577 shares in the last quarter. Finally, Palladium Partners LLC raised its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after purchasing an additional 523 shares during the period. 81.21% of the stock is owned by hedge funds and other institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.